Economie impact of HIV protease inhibitor therapy in the global use of health-care resources

HIV Medicine

Volumn 1, Issue 4, 2000, Pages 246-251

  Velasco, M ^a,b   Gomez, A ^a   Fernandez C ^a   Perez Cecilia E ^a   Tellez M J ^a   Roca, V ^c   Fernendez Cruz, A ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Av Diagonal 666 ^*  (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Cost; Diagnosis related group; Hiv protease inhibitor

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE PLANNING; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; SPAIN; TEACHING HOSPITAL; UTILIZATION REVIEW;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMAN; MALE; SPAIN;

EID: 0034305095     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00036.x     Document Type: Article

References (22)

1. Mouton Y, Alfandari S, Valette M et al. Impact of protease inhibitors on AIDS-defïning events and hospitalization in 10 French AIDS reference centres. AIDS 1997; 11: F101-F 105.
2. Egger M, Hirschel B, Francioli P étal. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV cohort study. BMJ 1997; 315: 1194-1199.
3. Palella FJ, Delaney KM, Moorman AC eraJ. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N EnglJ Med 1998; 338: 853-860.
4. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351: 228-210.
5. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N EnglJ Med 1997; 336: 1531-1532.
6. Domingo P, Guardiola JM, Ris J, Nolla J. The impact of new antiretroviral regimens on HIV-associated hospital admissions and deaths. AIDS 1998; 12: 529-543.
7. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Cost of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-969.
8. Mocroft A, Barry S, Sabin ÇA étal. The changing pattern of admissions to a London hospital of patients with HIV 1988-97. AIDS 1999; 13: 1255-1261.
9. Bozzette SA, Beny SH, Duan N étal. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897-1904.
10. Health Systems Management Group. DRG refinement with specific comorbidities and complications: a synthesis of current approaches to patient classification. Final report. New Haven: HSMG/SOM/Yale University, 1989.
11. International Classification of Diseases (1999) Ninth Revision Clinical Modification. (ICD-9-CM). National Center for Health Statistics home page. In: http://www.cdc.gov/nchswww/about/ otheract/icd9/abticd9.html
12. Fetter RB, Youngsoo S, Freeman JL, Averill RF, Thomson JD. Case mix definition by diagnostic-related groups. Med Care 1984;18(Suppl): 1-53.
13. Fetter RB. Hospital payment based on diagnosis-related groups. JSoc Health Syst 1992; 3: 4-15.
14. Center for Disease Control. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. A/AftVR 1992; 41(RR-17): 1-19.
15. All-patient Diagnosis Related Groups (AP-DRGs) (1996) 3M Health Information Systems. Version 12.0. New York: New York State Department of Health, Division of Health Care Financing (DHCF).
16. Gestion analitica resultados. Servicios funcionales finales y no finales (Proyecto Signo). Subdirecciôn General de Atencion Especializada. Direction General del INSALUD (Instituto Nacional de la Salud). Madrid: Ministerio de Sanidad, 1997.
17. Keiser P, Kvanli MB, Turner D étal Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a veterans administration hospital. J Acquir Immune Deβc SyndrHum Retrovirol 1999; 20: 28-33.
18. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-291.
19. Anonymous. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
20. Quantin C, Entezam F, Brunet-Lecomte P, Lepage E, Guy H, Dusserre L. High cost factors for leukaemia and lymphoma patients: a new analysis of costs within these diagnosis related groups. J Epidemial Commun Health 1999; 53: 24-31.
21. Sendi PP, Bucher HC, HarrT etal. Cost-effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115-1122.
22. Carr A, Samara K, Burton S etal. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.